Physician profile
Dennis P Borczon
NPI 1487625521
$120,051.44
in general payments reported to CMS, 2019-2025
12 companies · $29K in 2025
The $29K reported for 2025 was more than what 99% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $8,542 · 2021: $13K · 2022: $14K · 2023: $23K · 2024: $21K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Honoraria: $27K · Travel and Lodging: $7,327 · Food and Beverage: $3,287 · Consulting Fee: $2,640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,000.00 |
| Honoraria | $27,488.00 |
| Travel and Lodging | $7,327.42 |
| Food and Beverage | $3,286.99 |
| Consulting Fee | $2,640.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $80,902.30 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $17,623.43 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $13,530.39 | 2019-2020 | |
| Shire North American Group INC | $3,814.13 | 2019 | |
| Sunovion Pharmaceuticals INC. | $2,830.26 | 2019-2021 | |
| Alkermes, INC. | $388.40 | 2022-2023 | Lybalvi |
| Ironshore Pharmaceuticals INC. | $348.20 | 2019-2021 | |
| Axsome Therapeutics, INC. | $325.37 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $87.49 | 2025 | Uzedy |
| Tris Pharma INC | $86.11 | 2020-2025 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $75.36 | 2025 | Jornay Pm |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $40.00 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Borczon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.